Cardiometabolic Forum

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: A prespecified analysis of the DAPA-CKD trial

Wheeler DC,

Jongs N,

Stefansson BV,

Chertow GM,

Greene T,

Hou FF,

Langkilde AM,

McMurray JJV,

Rossing P,

Nowicki M,

Wittmann I,

Correa-Rotter R,

Sjostrom CD,

Toto RD,

Heerspink HJL,

for the DAPA-CKD Trial Committees and Investigators

Nephrol Dial Transplant. 2021 Nov 25;gfab335. DOI: 10.1093/ndt/gfab335.

Patients with eGFR 25–75 mL/min/1.73m² and urinary albumin-to-creatinine ratio 200–5000 mg/g (22.6–565 mg/mol) were randomised 1:1 to dapagliflozin 10 mg once daily or matching placebo. This pre-specified analysis of the DAPA-CKD trial evaluated efficacy and safety of dapagliflozin in participants with FSGS confirmed by kidney biopsy.

Publications